Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R41/R42 Clinical Trial Optional)

US Dept. of Health & Human Services: National Institutes of Health (NIH)

Next deadline: Jan 14, 2024 (Letter of inquiry)

Later deadlines: Jan 14, 2024 (Letter of inquiry), Feb 14, 2024 (Full proposal), Aug 13, 2024 (Full proposal), Feb 14, 2025 (Full proposal)

Grant amount: Up to US $2,500,000

Funding uses: Research

Location of project: United States

Location of residency: United States

Overview:

This Notice of Funding Opportunity (NOFO) encourages Small Business Technology Transfer (STTR) grant applications from small business concerns (SBCs) proposing research projects directed towards commercialization for the development of novel, evidence-based, FDA-regulated medical products addressing the needs of patients suffering from opioid use disorders (OUD) and/or stimulant use disorders (StUD). Applications received under this NOFO may fall within two scientific areas, namely:

• pharmacotherapeutics (small molecules and biologics)and
• medical therapeutic and diagnostic devices, including software as a medical device.

This NOFO strives to contribute to the effort against the national opioid and psychostimulant emergency and offer new medical products for individuals, families, and communities affected by this devastating crisis. Small business companies that developed currently marketed technologies or are developing technologies for different indications and are interested in demonstrating that their FDA-regulated product has a potential application in the OUD/StUD space are encouraged to apply.

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.